AIM ImmunoTech enters research agreement with Japan's NIID to study Ampligen's effect on viral shedding

AIM ImmunoTech Inc.

Agreement with Japanese National Institute of Infectious Disease to evaluate Ampligen's capacity to prevent viral shedding in respiratory virus infections.
AIM supplies Ampligen free of charge; NIID conducts research; quarterly oral updates and final written report within 60 days.
Intellectual property ownership follows US inventorship law; no automatic license granted to NIID.
Agreement terminates upon completion, written agreement, or one year from effective date (May 8, 2023).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. entered into Material Transfer and Research Agreement with Japanese National Institute of Infectious Disease (effective 2023-05-22).

Action: entry
Agreement: collaboration
Counterparty: Japanese National Institute of Infectious Disease
Effective: 2023-05-22

Exact text from the filing

On May 22, 2023, AIM ImmunoTech Inc. (the “Company”) and the Japanese National Institute of Infectious Disease (the “JNIID”) entered into a Material Transfer and Research Agreement (the “Agreement).

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-019393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.